11,282 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Acquired by Proficio Capital Partners LLC

Proficio Capital Partners LLC bought a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 11,282 shares of the specialty pharmaceutical company’s stock, valued at approximately $408,000.

A number of other hedge funds have also bought and sold shares of SUPN. Smartleaf Asset Management LLC grew its holdings in shares of Supernus Pharmaceuticals by 219.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock valued at $47,000 after buying an additional 870 shares during the last quarter. Newbridge Financial Services Group Inc. acquired a new stake in Supernus Pharmaceuticals during the 4th quarter worth about $72,000. Venturi Wealth Management LLC purchased a new stake in Supernus Pharmaceuticals during the 4th quarter valued at about $92,000. KBC Group NV increased its holdings in shares of Supernus Pharmaceuticals by 53.1% in the fourth quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company’s stock valued at $97,000 after purchasing an additional 929 shares during the period. Finally, Janney Montgomery Scott LLC purchased a new position in shares of Supernus Pharmaceuticals in the fourth quarter worth about $211,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $36.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th. StockNews.com cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday.

Insider Activity at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 700 shares of Supernus Pharmaceuticals stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total value of $27,734.00. Following the completion of the transaction, the vice president now owns 10,149 shares of the company’s stock, valued at approximately $402,103.38. The trade was a 6.45 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Jonathan Rubin sold 927 shares of the stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the sale, the senior vice president now directly owns 7,853 shares in the company, valued at approximately $307,444.95. The trade was a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 11,104 shares of company stock worth $440,263. 9.30% of the stock is owned by corporate insiders.

Supernus Pharmaceuticals Stock Up 1.7 %

Shares of SUPN stock opened at $32.70 on Tuesday. Supernus Pharmaceuticals, Inc. has a 52-week low of $25.53 and a 52-week high of $40.28. The stock has a market cap of $1.83 billion, a PE ratio of 30.56 and a beta of 0.83. The business has a 50-day simple moving average of $35.58 and a 200-day simple moving average of $35.06.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.